Bruton Tyrosine Kinase (BTK) inhibitor

News

An early-stage drug that is being developed to tackle inflammatory and autoimmune diseases has been approved by the US regulator.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.